Surfactant therapy is the medical administration of exogenous surfactant. Surfactants used in this manner are typically instilled directly into the trachea.
Exogenous surfactant replacement therapy is effective in reducing RDS mortality and morbidity in preterm infants.
Poractant alfa, Calfactant, Beractant are the types of natural surfactants commercially available in the United States. Although data is sometimes conflicting, it appears that there are no significant differences among the available preparations.
Surfactant therapy is not used to treat adults with adult respiratory distress syndrome because the evidence regarding its effect on patient-important outcomes is inconsistent.